Vertex shares up after full-year product revenue guidance boost
Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.
Zacks.com on MSN5d
Vertex (VERX) Q3 Earnings and Revenues Surpass Estimates
Vertex (VERX) delivered earnings and revenue surprises of 14.29% and 2.96%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo Finance4d
Q3 2024 Vertex Inc Earnings Call
Good day and welcome to the Vertex Inc third quarter, 2024 earnings conference call. All participants will be in listen-only mode. Should you need assistance? Please signal a conference specialist by ...
Investing6d
Vertex shares hold strong on upbeat Q3 results and outlook
On Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX) maintained a positive stance from Oppenheimer, with a reiterated Outperform rating and a steady price target of $540.00.
Q3 2024 Vertex Pharmaceuticals Inc Earnings Call
Good day and welcome to the Vertex Pharmaceuticals third-quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to ...
Cystic fibrosis wonder drug dramatically raises patients' life expectancy by 8 years
Sufferers now living an extra eight years on average following a Daily Express campaign to help people get lifesaving ...
Oxford Mail1d
Bicester student inspired after pharmaceutical internship
A Bicester School Sixth Form student "rediscovered her love of learning" earlier this year following a summer internship at ...
pharmaphorum2d
Vertex scores double win with non-opioid pain drug
Vertex Pharma could be close to succeeding in ... A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with ...
devdiscourse6d
Global Health Developments: Breakthroughs and Challenges
Recent health news covers Vertex Pharmaceuticals' revenue uptick due to cystic fibrosis treatments, Britain's detection of ...
pharmaphorum4d
Vertex, Orum partner on safer pre-treatment for gene meds
Vertex Pharma has teamed up with Orum Therapeutics ... Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines pricing and ...
Le Lézard6d
Abry Partners and BHMS Announce Sale of Innovisk to Ryan Specialty
Abry Partners, a Boston-based private equity firm, and BHMS Investments, LP, a Connecticut-based private equity firm, have completed the sale of Innovisk to Ryan Specialty , a leading international ...
Morningstar5d
Positive Long-Term Outlook for Crispr Driven by Casgevy and Diverse Gene Editing Portfolio
Vertex will receive 60% and Crispr will receive 40% of ... which contributed to its withdrawal from the EU and UK markets. After a review of additional clinical data, the FDA approved Zynteglo in ...